Papillary Thyroid Carcinoma and Hashimoto’s Thyroiditis: New Insights into the Immunological Link

ABSTRACT

Hashimoto’s thyroiditis is the most common autoimmune disease, which is characterized by a cellular immune response with lymphatic infiltration of the thyroid gland mainly by T cells and B cells as well as by a humoral immune response leading to specific antibody production. Papillary thyroid carcinoma, the most common endocrine malignancy, is also characterized by broad immune cell infiltration. In recent years, a growing body of evidence has suggested a close connection between papillary thyroid carcinoma and Hashimoto’s thyroiditis. The mechanisms underlying the relationship between Hashimoto’s thyroiditis and papillary thyroid carcinoma, however, remain incompletely understood. One hallmark in the understanding of the immunological link between both diseases was the description of identical epitope-specific cytotoxic T cells as clear evidence for a close connection between Hashimoto’s thyroiditis und papillary thyroid carcinoma. In this review, we describe the role of Hashimoto’s thyroiditis in the development and prognosis of papillary thyroid cancer, the role of thyroid-specific antibodies in the diagnosis and outcome prediction of papillary thyroid carcinoma and the potential implication of this knowledge for cancer immunotherapy in general.

Keywords

Papillary thyroid carcinoma - Hashimoto’s thyroiditis - autoimmune disease

Publication History

Received: 30 September 2025

Accepted after revision: 09 November 2025

Article published online:
29 December 2025

• References

• 1 La Vecchia C, Malvezzi M, Bosetti C. et al. Thyroid cancer mortality and incidence: a global overview. Int J Cancer 2015; 136 (09) 2187-2195
• 2 Ajjan RA, Weetman AP. The Pathogenesis of Hashimoto’s Thyroiditis: Further Developments in our Understanding. Horm Metab Res 2015; 47 (10) 702-710
• 3 Pellegriti G, Frasca F, Regalbuto C. et al. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol 2013; 2013: 965212
• 4 Eichhorn W, Tabler H, Lippold R. et al. Prognostic factors determining long-term survival in well-differentiated thyroid cancer: an analysis of four hundred eighty-four patients undergoing therapy and aftercare at the same institution. Thyroid 2003; 13 (10) 949-958
• 5 Matsubayashi S, Kawai K, Matsumoto Y. et al. The correlation between papillary thyroid carcinoma and lymphocytic infiltration in the thyroid gland. J Clin Endocrinol Metab 1995; 80 (12) 3421-3424
• 6 Klubo-Gwiezdzinska J, Wartofsky L. Hashimoto thyroiditis: an evidence-based guide to etiology, diagnosis and treatment. Pol Arch Intern Med 2022; 132 (03) 16222
• 7 Conrad N, Misra S, Verbakel JY. et al Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK. Lancet 2023; 401 10391 1878-1890
• 8 Ragusa F, Fallahi P, Elia G. et al. Hashimotos’ thyroiditis: Epidemiology, pathogenesis, clinic and therapy. Best Pract Res Clin Endocrinol Metab 2019; 33 (06) 101367
• 9 Rotondi M, Coperchini F, Pignatti P. et al. Interferon-gamma and tumor necrosis factor-alpha sustain secretion of specific CXC chemokines in human thyrocytes: a first step toward a differentiation between autoimmune and tumor-related inflammation?. J Clin Endocrinol Metab 2013; 98 (01) 308-313
• 10 Ehlers M, Schott M. Hashimoto’s thyroiditis and papillary thyroid cancer: are they immunologically linked?. Trends Endocrinol Metab 2014; 25 (12) 656-664
• 11 Gonzalez-Amaro R, Marazuela M. T regulatory (Treg) and T helper 17 (Th17) lymphocytes in thyroid autoimmunity. Endocrine 2016; 52 (01) 30-38
• 12 Safdari V, Alijani E, Nemati M, Jafarzadeh A. Imbalances in T Cell-Related Transcription Factors Among Patients with Hashimoto’s Thyroiditis. Sultan Qaboos Univ Med J 2017; 17 (02) e174-e180
• 13 Fang D, Zhou L, Zheng B. Research Progress on the Immunological Correlation Between Papillary Thyroid Carcinoma and Hashimoto’s Thyroiditis. J Immunol Res 2025; 2025: 7192808
• 14 Ohue Y, Nishikawa H. Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?. Cancer Sci 2019; 110 (07) 2080-2089
• 15 French JD, Weber ZJ, Fretwell DL. et al. Tumor-associated lymphocytes and increased FoxP3+ regulatory T cell frequency correlate with more aggressive papillary thyroid cancer. J Clin Endocrinol Metab 2010; 95 (05) 2325-2333
• 16 Tanaka A, Sakaguchi S. Targeting Treg cells in cancer immunotherapy. Eur J Immunol 2019; 49 (08) 1140-1146
• 17 Takeuchi Y, Nishikawa H. Roles of regulatory T cells in cancer immunity. Int Immunol 2016; 28 (08) 401-409
• 18 Shitara K, Nishikawa H. Regulatory T cells: a potential target in cancer immunotherapy. Ann N Y Acad Sci 2018; 1417 (01) 104-115
• 19 Halvorsen EC, Mahmoud SM, Bennewith KL. Emerging roles of regulatory T cells in tumour progression and metastasis. Cancer Metastasis Rev 2014; 33 (04) 1025-1041
• 20 Togashi Y, Shitara K, Nishikawa H. Regulatory T cells in cancer immunosuppression - implications for anticancer therapy. Nat Rev Clin Oncol 2019; 16 (06) 356-371
• 21 Sakaguchi S. Naturally arising Foxp3-expressing CD25⁺CD4⁺ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005; 6 (04) 345-352
• 22 Liu Y, Yun X, Gao M. et al. Analysis of regulatory T cells frequency in peripheral blood and tumor tissues in papillary thyroid carcinoma with and without Hashimoto’s thyroiditis. Clin Transl Oncol 2015; 17 (04) 274-280
• 23 Nabeshima A, Matsumoto Y, Fukushi J. et al. Tumour-associated macrophages correlate with poor prognosis in myxoid liposarcoma and promote cell motility and invasion via the HB-EGF-EGFR-PI3K/Akt pathways. Br J Cancer 2015; 112 (03) 547-555
• 24 Ivanova K, Manolova I, Ignatova MM, Gulubova M. Immunohistochemical Expression of TGF-Beta1, SMAD4, SMAD7, TGFbetaRII and CD68-Positive TAM Densities in Papillary Thyroid Cancer. Open Access Maced J Med Sci 2018; 6 (03) 435-441
• 25 Liu J, Geng X, Hou J, Wu G. New insights into M1/M2 macrophages: key modulators in cancer progression. Cancer Cell Int 2021; 21 (01) 389
• 26 Kranz LM, Diken M, Haas H. et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature 2016; 534 (7607) 396-401
• 27 Feng C, Tao Y, Yu C. et al. Integrative single-cell transcriptome analysis reveals immune suppressive landscape in the anaplastic thyroid cancer. Cancer Gene Ther 2023; 30 (12) 1598-1609
• 28 Binnemars-Postma K, Bansal R, Storm G, Prakash J. Targeting the Stat6 pathway in tumor-associated macrophages reduces tumor growth and metastatic niche formation in breast cancer. FASEB J 2018; 32 (02) 969-978
• 29 Hebenstreit D, Wirnsberger G, Horejs-Hoeck J, Duschl A. Signaling mechanisms, interaction partners, and target genes of STAT6. Cytokine Growth Factor Rev 2006; 17 (03) 173-188
• 30 Sulaieva O, Chernenko O, Selesnov O. et al. Mechanisms of the Impact of Hashimoto Thyroiditis on Papillary Thyroid Carcinoma Progression: Relationship with the Tumor Immune Microenvironment. Endocrinol Metab (Seoul) 2020; 35 (02) 443-455
• 31 Ryder M, Ghossein RA, Ricarte-Filho JC. et al. Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr Relat Cancer 2008; 15 (04) 1069-1074
• 32 Ehlers M, Thiel A, Bernecker C. et al. Evidence of a combined cytotoxic thyroglobulin and thyroperoxidase epitope-specific cellular immunity in Hashimoto’s thyroiditis. J Clin Endocrinol Metab 2012; 97 (04) 1347-1354
• 33 Ehlers M, Kuebart A, Hautzel H. et al. Epitope-Specific Antitumor Immunity Suppresses Tumor Spread in Papillary Thyroid Cancer. J Clin Endocrinol Metab 2017; 102 (07) 2154-2161
• 34 Xu J, Ding K, Mu L. et al. Hashimoto’s Thyroiditis: A “Double-Edged Sword” in Thyroid Carcinoma. Front Endocrinol (Lausanne) 2022; 13: 801925
• 35 Resende de Paiva C, Gronhoj C, Feldt-Rasmussen U, von Buchwald C. Association between Hashimoto’s Thyroiditis and Thyroid Cancer in 64,628 Patients. Front Oncol 2017; 7: 53
• 36 Boi F, Pani F, Calo PG. et al. High prevalence of papillary thyroid carcinoma in nodular Hashimoto’s thyroiditis at the first diagnosis and during the follow-up. J Endocrinol Invest 2018; 41 (04) 395-402
• 37 Jackson D, Handelsman RS, Farra JC, Lew JI. Increased Incidental Thyroid Cancer in Patients With Subclinical Chronic Lymphocytic Thyroiditis. J Surg Res 2020; 245: 115-118
• 38 Harmantepe AT, Ozdemir K, Bayhan Z, Kocer B. The Underestimated Impact of Hashimoto Thyroiditis on Thyroid Papillary Carcinoma. Updates Surg 2024; 76 (03) 1085-1089
• 39 Zhang Y, Dai J, Wu T. et al. The study of the coexistence of Hashimoto’s thyroiditis with papillary thyroid carcinoma. J Cancer Res Clin Oncol 2014; 140 (06) 1021-1026
• 40 Rahbari R, Zhang L, Kebebew E. Thyroid cancer gender disparity. Future Oncol 2010; 6 (11) 1771-1779
• 41 Liang J, Zeng W, Fang F. et al. Clinical analysis of Hashimoto thyroiditis coexistent with papillary thyroid cancer in 1392 patients. Acta Otorhinolaryngol Ital 2017; 37 (05) 393-400
• 42 Lau J, Lee J, Mahipal M. et al. Hashimoto’s thyroiditis on outcomes in papillary thyroid cancer revisited: experience from South East Asia. Ann R Coll Surg Engl 2022; 104 (06) 465-471
• 43 Ma H, Li L, Li K. et al. Hashimoto’s thyroiditis, nodular goiter or follicular adenoma combined with papillary thyroid carcinoma play protective role in patients. Neoplasma 2018; 65 (03) 436-440
• 44 Scheffel RS, Dora JM, Maia AL. BRAF mutations in thyroid cancer. Curr Opin Oncol 2022; 34 (01) 9-18
• 45 Wang Y, Zheng J, Hu X. et al. A retrospective study of papillary thyroid carcinoma: Hashimoto’s thyroiditis as a protective biomarker for lymph node metastasis. Eur J Surg Oncol 2023; 49 (03) 560-567
• 46 Song WJ, Um IC, Kwon SR. et al. Predictive factors of lymph node metastasis in papillary thyroid cancer. PLoS One 2023; 18 (11) e0294594
• 47 Battistella E, Pomba L, Costantini A. et al. Hashimoto’s Thyroiditis and Papillary Cancer Thyroid Coexistence Exerts a Protective Effect: a Single Centre Experience. Indian J Surg Oncol 2022; 13 (01) 164-168
• 48 Zhu F, Shen YB, Li FQ. et al. The Effects of Hashimoto Thyroiditis on Lymph Node Metastases in Unifocal and Multifocal Papillary Thyroid Carcinoma: A Retrospective Chinese Cohort Study. Medicine (Baltimore) 2016; 95 (06) e2674
• 49 Wang L, Chen J, Yuan X. et al. Lymph node metastasis of papillary thyroid carcinoma in the context of Hashimoto’s thyroiditis. BMC Endocr Disord 2022; 22 (01) 12
• 50 Viola N, Agate L, Caprio S. et al. Thyroid autoimmunity, thyroglobulin autoantibodies, and thyroid cancer prognosis. Endocr Relat Cancer 2023; 30 (07) e230042
• 51 Ma B, Chen X, Zhao Z. et al. Coexisting CLT in PTC is an independent predictor of tumor aggressiveness for patients aged under 55: a retrospective analysis of 635 patients. BMC Endocr Disord 2022; 22 (01) 55
• 52 Yan C, He X, Chen Z, Wang Y. Central Compartment Lymph Nodes Have Distinct Metastatic Patterns in Different Age Groups. Front Endocrinol (Lausanne) 2022; 13: 807431
• 53 Xu S, Huang H, Qian J. et al. Prevalence of Hashimoto Thyroiditis in Adults With Papillary Thyroid Cancer and Its Association With Cancer Recurrence and Outcomes. JAMA Netw Open 2021; 4 (07) e2118526
• 54 Tang Q, Pan W, Peng L. Association between Hashimoto thyroiditis and clinical outcomes of papillary thyroid carcinoma: A meta-analysis. PLoS One 2022; 17 (06) e0269995
• 55 Kwak HY, Chae BJ, Eom YH. et al. Does papillary thyroid carcinoma have a better prognosis with or without Hashimoto thyroiditis?. Int J Clin Oncol 2015; 20 (03) 463-473
• 56 Ryu YJ, Yoon JH. Chronic lymphocytic thyroiditis protects against recurrence in patients with cN0 papillary thyroid cancer. Surg Oncol 2020; 34: 67-73
• 57 Marotta V, Sciammarella C, Chiofalo MG. et al. Hashimoto’s thyroiditis predicts outcome in intrathyroidal papillary thyroid cancer. Endocr Relat Cancer 2017; 24 (09) 485-493
• 58 Noel JE, Thatipamala P, Hung KS. et al. Pre-Operative Antithyroid Antibodies in Differentiated Thyroid Cancer. Endocr Pract 2021; 27 (11) 1114-1118
• 59 Li L, Shan T, Sun X. et al. Positive Thyroid Peroxidase Antibody and Thyroglobulin Antibody are Associated With Better Clinicopathologic Features of Papillary Thyroid Cancer. Endocr Pract 2021; 27 (04) 306-311
• 60 McLeod DSA, Bedno SA, Cooper DS. et al. Pre-existing Thyroid Autoimmunity and Risk of Papillary Thyroid Cancer: A Nested Case-Control Study of US Active-Duty Personnel. J Clin Oncol 2022; 40 (23) 2578-2587
• 61 Mazzaferri EL, Robbins RJ, Spencer CA. et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2003; 88 (04) 1433-1441
• 62 Rubello D, Casara D, Girelli ME. et al. Clinical meaning of circulating antithyroglobulin antibodies in differentiated thyroid cancer: a prospective study. J Nucl Med 1992; 33 (08) 1478-1480
• 63 Chung JK, Park YJ, Kim TY. et al. Clinical significance of elevated level of serum antithyroglobulin antibody in patients with differentiated thyroid cancer after thyroid ablation. Clin Endocrinol (Oxf) 2002; 57 (02) 215-221
• 64 Kim WG, Yoon JH, Kim WB. et al. Change of serum antithyroglobulin antibody levels is useful for prediction of clinical recurrence in thyroglobulin-negative patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 2008; 93 (12) 4683-4689
• 65 Reverter JL, Rosas-Allende I, Puig-Jove C. et al. Prognostic Significance of Thyroglobulin Antibodies in Differentiated Thyroid Cancer. J Thyroid Res 2020; 2020: 8312628
• 66 Haugen BR, Alexander EK, Bible KC. et al. American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016; 26 (01) 1-133
• 67 Chiovato L, Latrofa F, Braverman LE. et al Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. Ann Intern Med 2003; 139 5 Pt 1 346-351
• 68 Rosario PW, Carvalho M, Mourao GF, Calsolari MR. Comparison of Antithyroglobulin Antibody Concentrations Before and After Ablation with 131I as a Predictor of Structural Disease in Differentiated Thyroid Carcinoma Patients with Undetectable Basal Thyroglobulin and Negative Neck Ultrasonography. Thyroid 2016; 26 (04) 525-531
• 69 Ernaga-Lorea A, Hernandez-Morhain MC, Anda-Apinaniz E. et al. Prognostic value of change in anti-thyroglobulin antibodies after thyroidectomy in patients with papillary thyroid carcinoma. Clin Transl Oncol 2018; 20 (06) 740-744
• 70 Sun D, Zheng X, He X. et al. Prognostic value and dynamics of antithyroglobulin antibodies for differentiated thyroid carcinoma. Biomark Med 2020; 14 (18) 1683-1692
• 71 Lupoli GA, Okosieme OE, Evans C. et al. Prognostic significance of thyroglobulin antibody epitopes in differentiated thyroid cancer. J Clin Endocrinol Metab 2015; 100 (01) 100-108
• 72 de Filette J, Andreescu CE, Cools F. et al. A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors. Horm Metab Res 2019; 51 (03) 145-156
• 73 Zitvogel L, Perreault C, Finn OJ, Kroemer G. Beneficial autoimmunity improves cancer prognosis. Nat Rev Clin Oncol 2021; 18 (09) 591-602
• 74 Lei M, Michael A, Patel S, Wang D. Evaluation of the impact of thyroiditis development in patients receiving immunotherapy with programmed cell death-1 inhibitors. J Oncol Pharm Pract 2019; 25 (06) 1402-1411